Galectin-3 and beclin1/Atg6 genes in human cancers: Using cDNA tissue panel, qRT-PCR, and logistic regression model to identify cancer cell biomarkers

PLoS ONE

Volumn 6, Issue 10, 2011, Pages

  Idikio, Halliday A ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; MESSENGER RNA; TUMOR MARKER; APOPTOSIS REGULATORY PROTEIN; BECN1 PROTEIN, HUMAN; GALECTIN 3; MEMBRANE PROTEIN;

ADOLESCENT; ADULT; AGED; ARTICLE; BECLIN 1 GENE; BREAST CANCER; CANCER RESEARCH; CANCER SURVIVAL; CANCER TISSUE; COLON CANCER; CONTROLLED STUDY; FEMALE; GALECTIN 3 GENE; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; KIDNEY CANCER; LIVER CANCER; LOGISTIC REGRESSION ANALYSIS; LUNG CANCER; MALE; NUCLEOTIDE SEQUENCE; OVARY CANCER; PROSTATE CANCER; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; THYROID CANCER; TUMOR GENE; UPREGULATION; GENETICS;

APOPTOSIS REGULATORY PROTEINS; DNA, COMPLEMENTARY; GALECTIN 3; HUMANS; MEMBRANE PROTEINS; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL;

EID: 80054778471     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0026150     Document Type: Article

References (92)

1. Taube S, Clark G, Dancey J, McShane L, Sigman C, et al. (2009) A perspective on Challenges and Issues in Biomarker Development and Drug and Biomarker Codevelopment. J Natl Cancer Inst 101: 1453-1463.
2. Ludwig J, Weinstein J, (2005) Biomarkers in Cancer Staging, Prognosis and Treatment Selection. Nature Reviews Cancer 5: 845-856.
3. Sawyers C, (2008) The cancer biomarker problem. Nature Reviews Cancer 452: 548-552.
4. Jiang W, Freidin B, Simon R, (2007) Biomarker-Adaptive Threshold Design: A Procedure for Evaluating Treatment With Possible Biomarker-Dfined Subset Effect. J Natl Cancer Inst 99: 1036-1043.
5. Amaravadi R, Thompson C, (2007) The Roles of Therapy-Induced Autophagy and Necrosis in Cancer Treatment. Clin Cancer Res 13: 7271-7279.
6. Kondo Y, Kanzawa T, Sawaya R, Kondo S, (2005) The role of autophagy in cancer development and response to therapy. Nature Reviews Cancer 5: 726-734.
7. Goldstein P, Kroemer G, (2007) A multiplicity of cell death pathways. EMBO Reports 8: 829-833.
8. Okada H, Mak T, (2004) Pathways of apoptotic and non-apoptotic death in tumor cells. Nature Reviews Cancer 4: 592-603.
9. Vandennabeele P, Galluzzi L, Berghe T, Kroemer G, (2010) Molecular mechanisms of necroptosis: an ordered cellular explosion. Nature Reviews Molecular and Cell Biology 11: 700-714.
10. Vandennabeele P, Declercq W, Van Herreweghe F, Vanden Berghe T, (2010) The role of the kinases RIP1 and RIP3 in TNF-induced necrosis. Science Signaling 3: re4.
11. Galluzzi L, Kepp O, Kroemer G, (2009) RIP Kinases Initiate Programmed Necrosis. Journal of Molecular Cell Biology 1: 8-10.
12. Declercq W, Vanden Berghe T, Vandennabeele P, (2009) RIP Kinases at the Crossroads of Cell Death and Survival. Cell 138: 229-232.
13. Hitomi J, Christopherson D, Ng A, Yao J, Degterev A, et al. (2008) Identification of a molecular signaling network that requires a cellular necrotic cell death pathway by a genome wide siRNA screen. Cell 135: 1311-1323.
14. Zhang D, Shao J, Lin J, Zhang N, Lu B, et al. (2009) RIP3, an energy metabolism regulator that switches TNF-induced cell death from apoptosis to necrosis. Science 325: 332-336.
15. Lambert L, Qiao N, Hunt K, Lambert D, Mills G, et al. (2008) Autophagy: A Novel Mechanism of Synergistic Cytotoxity between Doxorubicin and Roscovitine in a Sarcoma Model. Cancer Research 68: 7966-7974.
16. Thorburn A, (2008) Apoptosis and Autophagy: regulatory connections between two supposedly different processes. Apoptosis 13: 1-9.
17. Akdemir F, Farkas R, Chen P, Juhasz G, Medved'ova L, et al. (2006) Autophagy occurs upstream or parallel to the apoptosome during histolytic cell death. Development 133: 1457-1465.
18. Hanahan D, Weinberg R, (2000) The Hallmarks of Cancer. Cell 100: 57-70.
19. Apel A, Herr I, Schwarz H, Rodemenn H, Mayer A, (2008) Blocked Autophagy Sensitizes Resistant carcinoma Cells to Radiation Therapy. Cancer Research 68: 1485-1494.
20. Boya P, Gonzalez-Polo R-A, Casares N, Perfettini J-L, Dessen P, et al. (2005) Inhibition of Macroautophagy Triggers Apoptosis. Molecular and Cellular Biology 25: 1025-1040.
21. Maiuri M, Zalckvar E, Kimchi A, Kroemer G, (2007) Self-eating and self-killing: crosstalk between autophagy and apoptosis. Nature Reviews Molecular Cell Biology 8: 741-752.
22. Yousefi S, Perozzo R, Schmid I, Ziemiecki A, Schaffner T, et al. (2006) Calpain-mediated clevage of Atg5 switches autophagy to apoptosis. Nature Cell Biology 8: 1124-1132.
23. Liu F, Patterson R, Wang J, (2002) Intracellular functions of galectins. Biochem Biophys Acta 1572: 263-273.
24. Nakahara S, Oka N, Raz A, (2005) On the role of galectin-3 in cancer apoptosis. Apoptosis 10: 267-275.
25. Shalom-Feuerstein R, Cooks T, Raz A, Kloog Y, (2005) Galectin-3 Regulates a Molecular Switch from N-Ras to K-Ras Usage in Human Breast Carcinoma Cells. Cancer Research 65: 7292-7300.
26. Hsu D, Liu F-T, (2004) Regulation of cellular homeostasis by galectins. Glycoconjugate J 19: 507-515.
27. Fukumori T, Kanayama H, Raz A, (2007) The role of galectin-3 in cancer drug resistance. Drug Resist Update 10: 101-108.
28. Chiariotti L, Salvatore P, Frunzio R, Bruni C, (2004) Galectin genes: Regulation of expression. Glycoconjugate J 19: 441-449.
29. Thijssen V, Hulsmans S, Griffioen A, (2008) The Galectin Profile of the Endothelium: Altered Expression and Localization in Activated and Tumor Endothelial Cells. American J Pathology 172: 545-553.
30. Takenaka Y, Fukumori T, Raz A, (2004) Galectin-3 and metastasis. Glycoconjugate J 19: 543-549.
31. Liu F-T, Rabinovich G, (2005) Galectins as modulators of tumor progression. Nature Reviews Cancer 5: 29-41.
32. Shimura T, Takenaka Y, Fukumori T, Tsutsumi S, Okada K, et al. (2005) Implication of Galectin-3 in Wnt Signaling. Cancer Research 65: 3535-3537.
33. Akahani S, Nangia-Makker P, Inohara H, Kim HC, Raz A, (1997) Galectin-3: A novel Anti-apoptotic Molecule with a Functional BH1(NWGR) Domain of Bcl-2 Family. Cancer Research 57: 5272-5276.
34. Yang R-Y, Hsu D, Liu F-T, (1996) Expression of galectin-3 modulates T-cell growth and apoptosis. PNAS 93: 6737-6742.
35. Yue Z, Jin S, Yang C, Levine A, Heintz N, (2003) Beclin1, an autophagy gene essential for early embryonic development, is a haploinsufficient tumor suppressor. PNAS 100: 1507-1582.
36. Qu X, Yu J, Bhagat G, Furuya N, Hibshoosh H, et al. (2003) Promotion of tumorigenesis by heterozygous disruption of the beclin1 autophagy gene. J Clin Invest 112: 1809-1820.
37. Sun Q, Fan W, Chen K, Ding X, Chen S, et al. (2008) Identification of Barkor as a mammalian autophgy-specific factor for Beclin-1 and class III phosphotidylinositol 3-kinase. PNAS 196: 19211-19216.
38. Cao Y, Klionsky D, (2007) Physiological functions of Atg6/Beclin1: a unique autophagy-related protein. Cell Research 17: 839-849.
39. Polager S, Ofir M, Ginsberg D, (2008) E2F1 reugulates autophagy and the transcription of autophagy genes. Oncogene 27: 4860-4864.
40. Maiuri M, Tasdemir E, Criollo A, Morselli E, Vicencio J, et al. (2009) Control of autophagy by oncogenes and tumor suppressor genes. Cell Death and Differentiation 16: 87-93.
41. Abida W, Gu W, (2008) p53-Dependent and p53-Independent Activation of Autophagy by ARF. Cancer Research 68: 352-357.
42. Levine B, Abrams J, (2007) p53: The Janus of autophagy? Nature Cell Biology 10: 637-639.
43. Criollo A, Maiuri M, Tasdemir E, Vitale I, Fiebig A, et al. (2007) Regulation of autophagy by inositol triphosphate receptor. Cell Death and Differentiation 14.
44. Pattingre S, Tassa A, Qu X, Garuti R, Liang X, et al. (2005) Bcl-2 Antiapoptotic Proteins Inhibit Beclin 1-Dependent Autophagy. Cell 122: 927-939.
45. Oka N, nakahara S, Takenaka Y, Fukumori T, Hogan V, et al. (2005) Galectin-3 Inhibits Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Induced Apoptosis by Activating Akt in Human Bladder Carcinoma Cells. Cancer Research 65: 7546-7553.
46. Zeng X, yan T, Schupp J, Seo Y, Kinsella T, (2007) DNA Mismatch Repair Initiates 6-Thioguanine-Induced Autophagy through p53 Activation in Human Tumor Cells. Clin Cancer Res 13: 1315-1321.
47. Paglin S, Hollister T, Delohery T, hackett N, McMahill M, et al. (2001) A Novel Response of Cancer Cells to Radiation Involves Autophagy and Formation of Acidic vesicles. Cancer Research 61: 439-444.
48. Kim K, Mutter R, Cao C, Albert J, Freeman M, et al. (2006) Autophagy for Cancer Therapy through Inhibition of Pro-apoptotic Proteins and Mammalian Target of Rapamycin. J Biol Chem 281: 36883-36890.
49. Wang X, Seed B, (2003) A PCR primer bank for quantitative gene expression analysis. Nucleic Acid Research 31: e154.
50. Zhao S, Fernald R, (2005) Comprehensive Algorithm for Quantitative Real-Time Polymerase Chain Reaction. J Computational Biology 12: 1047-1064.
51. Rutledge R, (2004) Sigmoidal curve-fitting redefines quantitative real-time PCR with the prospective of developing automated high-throughput applications. Nucleic Acid Research 32: e178.
52. Rutledge R, Stewart D, (2008) Critical evaluation of methods used to determine amplification efficiency refutes the exponential character of real-time PCR. BMC Molecular Biology 9: 96.
53. Rutledge R, Stewart D, (2008) A Kinetic-based sigmoidal model for the polymerase chain reaction and its application to high-capacity absolute quantitative real-time PCR. BMC Biotechnology 8: 47.
54. Ruijter J, Ramakers C, Hoogaars W, Karlen Y, Bakker O, et al. (2009) Amplification efficiency: linking baseline and bias in the analysis of quantitative PCR data. Nucleic Acid Research 37: e45.
55. Bustin S, Benes V, Garson J, Hellemans J, Huggett J, et al. (2009) The MIQE Guidelines: Minimum Information for Publication of Quantitative Real-Time PCR Experiments. Clinical Chemistry 55: 611-622.
56. Nakahara S, Oka N, Wang Y, Hogan V, Inohara H, et al. (2006) Characterization of the Nuclear Import Pathways of Galectin-3. Cancer Research 66: 9995-10006.
57. Liang X, Yu J, Brown K, Levine B, (2001) Beclin1 Contains a leucine-rich Nuclear Export Signal That is Required for its Autophagy and Tumor Supressor Function. Cancer Research 61: 3443-3449.
58. Kihara A, Kabeya Y, Ohsumi Y, Yoshimori T, (2001) Beclin-phosphatidylinositol 3-kinase complex functions at the trans-Golgi network. EMBO Reports 21: 330-335.
59. Pattingre S, Beth L, (2006) Bcl-2 Inhibition of Autophagy: A New Route to Cancer? Cancer Research 66: 2885-2888.
60. Rubinsztein D, Gestwicki J, Murphy L, Klionsky D, (2007) Potential therapeutic applications of autophagy. Nature Reveiws Drug Discovery 6: 304-312.
61. Glinsky V, Kiriakova G, Glinskii O, Mossine V, Mawhinney T, et al. (2009) Synthetic Galectin-3 Inhibitor Increases Metastatic Cancer Cell Sensitivity to Taxol-Induced Apoptosis In Vitro and In Vivo. Neoplasia 11: 901-909.
62. Lin C, Whang E, Donner D, Jiang X, Price B, et al. (2009) Galectin-3 targeted therapy with small molecule inhibitor activates apoptosis and ehances both chemosensitivity and radiosensitivity in papillary thyroid cancer. Mol Cancer Res 7: 1655-1662.
63. Nangia-Makker P, Wang Y, Raz T, Tait L, Balan V, et al. (2010) Cleavage of galectin-3 by matrix metalloproteinases induces angiogenesis in breast cancer. International Journal of Cancer 127: 2530-2541.
64. Markowska A, Liu F-T, Panjwani N, (2010) Galectin-3 is an important mediator of VEGF- and bFGF-mediated angiogenesis. The Journal of Experimental Medicine 207: 1981-1993.
65. Idikio H, (1998) Galectin- expression in human breast carcinoma: correlation with cancer histologic grade. International Journal of Oncology 12: 1287-1290.
66. Shekar M, Nangia-Makker P, Tait L, Miller F, Raz A, (2004) Alterations in Galectin-3 Expression and Distribution Correlate with Breast Cancer Progression. Am J Pathol 165: 1931-1941.
67. Young A, Amin M, Moreno C, Lim S, Cohen C, et al. (2001) Expression Profiling of Renal Epithelial Neoplasms A method for Tumor Classification and Discovery of Diagnostic Molecular markers. American J Pathology 158: 1639-1651.
68. Bartolazzi A, D'Alessandria C, Parisella M, Signore A, Prete F, et al. (2008) Thyroid Cancer Imaging In Vivo by Targeting the Anti-Apoptotic Molecule Galectin-3. Plos One 3: e3768.
69. Grassadonia A, Tinari N, Iurisci I, Piccolo E, Cumashi A, et al. (2004) 90K(Mac-2 BP) and galectins in tumor progression and metastasis. Glycoconjugate J 19: 551-556.
70. Mourad-Zeidan A, Melnikova V, Wang H, Raz A, Bar-Eli M, (2008) Expression Profiling of Galectin-3-Depleted Melanoma Cells Reveals Its Major Role in Melanoma Cell Plasticity and Vasculogenic Mimicry. Am J Pathol 173: 1839-1852.
71. Fukumori T, Oka N, Takenaka Y, Nangia-Makker P, Elsamman E, et al. (2006) Galectin-3 Regulates Mitochondrial Stability and Antiapoptotic Function in Response to Anticancer Drug in Prostate Cancer. Cancer Research 66: 3114-3119.
72. Moon B-K, Lee Y, Battle P, Jessup J, Raz A, et al. (2001) Galectin-3 Protects Human Breast Carcinoma Cells against Nitric Oxide-Induced Apoptosis. Am J Pathol 159: 1055-1060.
73. Lavra L, Ulivieri A, Rinaldo C, Dominici R, Volante M, et al. (2009) Gal-3 is stimulated by gain-of-function p53 mutations and modulates chemoresistance in anaplastic thyroid carcinomas. J Pathol 218: 66-75.
74. Xu X, el-Naggar A, Lotan R, (1995) Differential expression of galectin-1 and galectin-3 in thyroid tumors. Potential diagnostic implications. American J Pathology 147: 815-822.
75. Finley D, Zhu B, Barden C, Fahey T, (2004) Discrimination of Benign and Malignant Thyroid Nodlues by Molecular Profiling. Annals of Surgery 240: 425-437.
76. Sato K, Tsuchihara K, Fujii S, Sugiyama M, Goya T, et al. (2007) Autophagy is Activated in Colorectal Cancer Cells and Contributes to Nutrient Deprivation. Cancer Research 67: 9677-9684.
77. Matsuda Y, Yamagiwa Y, Fukushima K, Ueno Y, Shimosegawa T, (2008) Expression of galectin-3 involved in progression of patients with hepatocellular carcinoma. Hepatol Res 38: 1098-1111.
78. Sakaki M, Fukumori T, Fukawa T, Eisamman E, Shiirevnyamba A, et al. (2010) Clinical significance of Galectin-3 in clear cell renal cell carcinoma. J Med Invest 57: 152-157.
79. Ellerhorst J, Stephens L, Nguyen T, Xu X, (2002) Effects of galectin-3 expression on growth and tumorigenicity of the prostate cancer cell line LNCaP. Prostate 50: 64-70.
80. Wang Y, Nangia-Makker P, Tait L, Balan V, Hogan V, et al. (2009) Regulation of prostate Cancer Progression by Galectin-3. Am J Pathol 174: 1515-1523.
81. Merseburger A, Kramer M, Hennenloter J, Simon P, Knapp J, et al. (2008) Involvement of Decreased Galectin-3 Expression in the Pathogenesis and Progression of Prostate Cancer. The Prostate 68: 72-77.
82. Ellerhorst J, Troncoso P, Xu X, Lee J, Lotan R, (1999) Galectin-1 and galectin-3 expression in human prostate tissue and prostate cancer. Urol Res 27: 362-367.
83. Ding Z-B, Shi Y-H, Zhou J, Qiu S-J, Xu Y, et al. (2008) Association of Autophagy Defect with a Malignant Phenotype and Poor Prognosis of Hepatocellular Carcinoma. Cancer Research 68: 9167-9175.
84. John S, Nayvelt I, Hsu H-C, Yang P, Liu W, et al. (2008) Regulation of Estrogenic Effects by Beclin1 in Breast Cancer Cells. Cancer Research 68: 7855.
85. Hernan-Antosiewicz A, Johnson D, Singh S, (2006) Sulforaphane Causes Autophagy to Inhibit Release of Cytochrome c and Apoptosis in Human Prostate cancer Cells. Cancer Research 66: 5828-5835.
86. Cao C, Subhawong T, Albert J, Kim K, Geng L, et al. (2006) Inhibition of Mammalian Target of Rapamycin or Apoptotic Pathway induces Autophagy and radiosensitizes PTEN Null Prostate Cancer Cells. Cancer Research 66: 10040-10047.
87. Turcotte S, Chan D, Sutphin P, Hay M, Denny W, et al. (2008) A Molecule Targeting VHL-Deficient Renal Cell Carcinoma that Induces Autophagy. Cancer Cell 14: 90-102.
88. Lu Z, Luo R, Lu Y, Zhang X, Yu Q, et al. (2008) The tumor suppressor gene ARH1 regulates autophgy and tumor dormancy in human ovarian cancer cells. J Clin Invest 118: 3817-3929.
89. Jin S, White E, (2007) Role of Autophagy in Cancer: Management of Metabolic Stress. Autophagy 3: 28-31.
90. Wang Y, Nangia-Makker P, Balan V, Hogan V, Raz A, (2010) Calpain activation through galectin-3 inhibition sensitizes prostate cancer cells to cisplatin treatment. Cell Death and Disease 1: e101.
91. Ahmed H, Cappello F, Rodolico VVasta GR, (2009) Evidence of Heavy Methylation in the Galectin-3 Promoter in Early Stages of Prostate Adenocarcinoma: Development and Validation of Methylated Marker for Early Diagnosis of Prostate Cancer. Translational Oncology 2 (3): 146-156.
92. Rutledge R, Stewart D, (2010) Assessing the Performance Capabilities of LRE-Based Assays for Absolute Quantitative Real-Time PCR. Plos ONE 5: e9731.